Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia

Sarah Elitzur, Nira Arad-Cohen, Shlomit Barzilai-Birenboim, Miriam Ben-Harush, Bella Bielorai, Ronit Elhasid, Tamar Feuerstein, Gil Gilad, Alexander Gural, Mira Kharit, Naomi Litichever, Ronit Nirel, Sigal Weinreb, Ofir Wolach, Amos Toren, Shai Izraeli, Elad Jacoby

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Tremendous progress in the therapy of pediatric acute lymphoblastic leukemia (ALL) has been achieved through combination cytotoxic chemotherapy, leading to high cure rates, at the cost of significant life-threatening toxicity. The bispecific T-cell engager blinatumomab, recently approved for relapsed/refractory ALL, has a unique nonmyelotoxic toxicity profile. As blinatumomab causes B-cell depletion, the safety of its use during severe chemotherapy-induced toxicity is unclear. We report 11 pediatric patients with ALL, treated with blinatumomab following overwhelming chemotherapy-associated toxicity, with recovery of all patients and successful bridging to further antileukemia therapy. Blinatumomab can be considered for rare patients who cannot tolerate cytotoxic therapy.

Original languageEnglish
Article numbere27898
JournalPediatric Blood and Cancer
Volume66
Issue number10
DOIs
StatePublished - 1 Jan 2019

Keywords

  • blinatumomab
  • childhood acute lymphoblastic leukemia
  • immunotherapy
  • treatment-related toxicity

Fingerprint

Dive into the research topics of 'Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia'. Together they form a unique fingerprint.

Cite this